130 related articles for article (PubMed ID: 19617465)
1. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
[TBL] [Abstract][Full Text] [Related]
3. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
Zhu YW; Mendelsohn A; Pendley C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):830-46. PubMed ID: 21084039
[TBL] [Abstract][Full Text] [Related]
5. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody.
Wang W; Leu J; Watson R; Xu Z; Zhou H
AAPS J; 2018 Apr; 20(3):63. PubMed ID: 29667047
[TBL] [Abstract][Full Text] [Related]
8. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
[TBL] [Abstract][Full Text] [Related]
10. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
11. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
Kavanaugh A; Mease P
J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
Khatri A; Othman AA
J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
[TBL] [Abstract][Full Text] [Related]
16. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis.
Hu C; Xu Z; Zhang Y; Rahman MU; Davis HM; Zhou H
J Clin Pharmacol; 2011 May; 51(5):639-48. PubMed ID: 20622199
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
18. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice.
Sharif K; Gendelman O; Langevitz P; Reitblat T; Watad A; Shoenfeld Y; Azuri J; Amital H; Bragazzi NL; Shovman O
Best Pract Res Clin Rheumatol; 2018 Oct; 32(5):692-700. PubMed ID: 31203927
[TBL] [Abstract][Full Text] [Related]
20. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
